Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q3 2023 · 10-Q
Revenue$1.80M$1.80M−8.3% vs Q3 2022 Net Income-$777.60K-$777.60KN/M vs Q3 2022 EPS Diluted-$0.29-$0.29N/M vs Q3 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived$1,007,286+359.7% Margins · derivedGross margin-12.9%−5.9 pt vs Q3 2022
Operating margin-39.6%−4.5 pt vs Q3 2022
Net margin-43.1%−2.9 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end